Preclinical development

Cytometry
#Drug development #Drug discovery #Mass cytometry #Phenotyping #Preclinical development

Digital Article: Immunophenotyping for targeted drug discovery

A new digital article is now available to download entitled ‘A comprehensive approach to immunophenotyping for targeted drug discovery and development’.  With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read… Read More

#News

#Drug development #Drug discovery #Mass cytometry #Phenotyping #Preclinical development

A comprehensive approach to immunophenotyping for targeted drug discovery and development

With high costs of therapeutic development, success relies on optimising preclinical and early clinical studies. Download this content-rich digital article to read about considerations for implementing and standardising high-dimensional immune profiling methods into drug development programs. Learn about different applications that demonstrate the robustness and reproducibility of a mass cytometry-based… Read More

#Resources

#Animal testing #ApconiX #Assays #FDA #Preclinical development

New podcast explores Sengenics’ i-Ome Discovery Microarrays

The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development #Sitting Down With podcast

Podcast: The FDA Modernisation Act 2.0 and seizure liability testing

The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as… Read More

#News

Human brain
#Animal testing #ApconiX #Assays #FDA #Preclinical development

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance… Read More

#Podcasts

Exosomes
#AAV #Codiak Biosciences #Evox Therapeutics #Mergers and acquisitions #Preclinical development

Evox Therapeutics acquires exosome AAV technology from Codiak

Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been… Read More

#Business & Investment #News

Diabetic eye disease
#Diabetes #Eye health #John Hopkins Medicine #Ophthalmology #Preclinical development

Experimental drug could prevent diabetic eye disease

New study results show that an experimental drug may prevent or slow vision loss in people with diabetes. The researchers at Wilmer Eye Institute, Johns Hopkins Medicine used mouse as well as human retinal organoids and eye cell lines in their investigations. Eye conditions… Read More

#Editor's Choice #News

Cutting the red ribbon
#Drug discovery #Omics #PerkinElmer #Preclinical development #Revvity

PerkinElmer’s Life Science and Diagnostics business becomes Revvity

PerkinElmer’s Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions company. Based on two words, ‘revolutionise’ (rev) and ‘vita’ (vit) meaning ‘life’ in Latin, Revvity will provide reagents, consumables, assays, instruments and software to customers from pharma and biotech,… Read More

#Business & Investment #News

Animal testing
#Animal models #Animal testing #Cancer research #Human disease models #Oncology #Preclinical development

Closing the translation gap in oncology drug development

Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable… Read More

#Cancer Research #Exclusive Content

Tumour microenvironment
#AACR 2023 #Avacta #Cancer research #Oncology #Preclinical development #Solid tumours

Data shows new therapy successfully targets solid tumours

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More

#Cancer Research #News

Medical research
#Mergers and acquisitions #Preclinical development #Preclinical investigations #R&D #Research services

BioIVT acquires research services company XenoTech

BioIVT has acquired XenoTech, a provider of products and services for preclinical testing that specialises in ADME, DMPK and DDI testing of potential drug candidates.  Through the acquisition, BioIVT aims to expand the portfolio of research models and services that are available to its clients to support… Read More

#News

Antibiotics
#Antibiotics #Antimicrobial resistance (AMR) #Preclinical development

Nosopharm brings antibiotic one step closer to clinical development

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. The company’s NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins and is being developed alongside GNA NOW, a European Consortium funded by the Innovative Medicines… Read More

#News

#Antibodies #Covid-19 #Drug development #Drug discovery #Preclinical development #Therapeutics

Highlights of Carterra’s Bamlanivimab story

A recent sponsored DDW Sitting Down With podcast covered the bamlanivimab story and how this therapeutic went from lab to clinic in eight months during the pandemic. It is available to listen to here. Lu Rahman selects some of the highlights of this chat with Bryan Jones, Senior Research Fellow, BioTechnology Discovery Research, Eli Lilly and Company and Dan Bedinger, Application… Read More

#Covid-19 #Exclusive Content #News

#Assay #Drug development #Drug toxicity #Preclinical development #Toxicology

Enhancing the predictability of drug toxicity and efficacy

There is an unmet clinical need in drug development for in vitro models that reduce the risk of drug-induced toxicity and late-stage drug attrition. In this webinar, hosted on May 26 2021, two expert speakers discuss how researchers can enhance the predictability of pre-clinical drug development. This webinar, Enhancing the predictability of… Read More

#Editor's Choice #News

#Assays #Clinical trials #Drug toxicity #Preclinical development #Toxicology

Driving the success of predictability in preclinical development 

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases,… Read More

#Editor's Choice #News